Kenadin 10 Injection contains Phytomenadione (10 mg/ml), a synthetic form of vitamin K1 used primarily for the prevention and treatment of vitamin K deficiency and associated bleeding disorders. It plays a crucial role in the synthesis of clotting factors II, VII, IX, and X, as well as proteins C and S, which are essential for normal blood coagulation. Kenadin 10 Injection is indicated in conditions such as hemorrhagic disease of the newborn, prophylaxis and treatment of hypoprothrombinemia due to vitamin K deficiency, and reversal of over-anticoagulation caused by vitamin K antagonists like warfarin. The injection is administered intramuscularly or intravenously, depending on clinical requirements, with dosage tailored to the severity of the deficiency and patient response. It is contraindicated in patients with known hypersensitivity to phytomenadione or any component of the formulation. Caution is advised in patients with liver disease or those receiving anticoagulant therapy. Adverse reactions are rare but may include hypersensitivity reactions such as anaphylaxis, erythema, or pain at the injection site. Kenadin 10 Injection should be stored at controlled room temperature and protected from light to maintain stability and efficacy. Proper administration and monitoring are essential to ensure optimal therapeutic outcomes.